{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:00:42Z","timestamp":1759960842899},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/bor.0b013e3283060778","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T07:07:22Z","timestamp":1218524842000},"page":"613-618","source":"Crossref","is-referenced-by-count":38,"title":["Update on biologics in juvenile idiopathic arthritis"],"prefix":"10.1097","volume":"20","author":[{"given":"Norman T","family":"Ilowite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/art.22837","article-title":"The future of pediatric rheumatology: many questions remain","volume":"56","author":"Lehman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/03009740601089234","article-title":"Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis","volume":"36","author":"Levalampi","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"R4-18-20210128","first-page":"2092","article-title":"Multiple alloantibodies after transfusion in an infant treated with infliximab","volume":"15","author":"Tyler","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-18-20210128","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3109\/s10165-007-0634-3","article-title":"Switching the therapy from etancercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis","volume":"7","author":"Nerome","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R6-18-20210128","first-page":"S292","article-title":"Adalimumab is safe and effective during long-term treatment of patients with juvenile rheumatoid arthritis: results from a 2-year study","volume":"56","author":"Lovell","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00044011-200323080-00003","article-title":"Quality-of-life in juvenile rheumatoid arthritis patients treated with etanercept","volume":"8","author":"Robinson","year":"2003","journal-title":"Clin Drug Investig"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2006.067629","article-title":"Effectiveness of a weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study","volume":"66","author":"Prince","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R9-18-20210128","first-page":"2481","article-title":"Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis","volume":"34","author":"Vojvodich","year":"2007","journal-title":"J Rheumatol"},{"key":"R10-18-20210128","first-page":"S291","article-title":"Efficacy of abatacept in different sub-populations of juvenile idiopathic arthritis (JIA): results of a randomized withdrawal study","volume":"56","author":"Giannini","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R11-18-20210128","first-page":"S292","article-title":"Abatacept treatment of juvenile idiopathic arthritis (JIA): safety report","volume":"56","author":"Lovell","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R12-18-20210128","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1084\/jem.20070070","article-title":"Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade","volume":"204","author":"Allantaz","year":"2007","journal-title":"J Exp Med"},{"key":"R13-18-20210128","first-page":"119","article-title":"Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (anakinra)","volume":"25","author":"Kone-Paut","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R14-18-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.rhu.0000208650.99508.4e","article-title":"Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis","volume":"12","author":"Mirkinson","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R15-18-20210128","first-page":"S514","article-title":"Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA)","volume":"56","author":"Lovell","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/art.22118","article-title":"Successful use of a humanized antiinterleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis","volume":"54","author":"Okuda","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R17-18-20210128","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF agents","volume":"149","author":"Saurenmann","year":"2006","journal-title":"J Pediatr"},{"key":"R18-18-20210128","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis","volume":"66","author":"Tynjala","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/ard.2006.065441","article-title":"Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease","volume":"66","author":"Sharma","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R20-18-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R21-18-20210128","first-page":"1341","article-title":"Biological response modifier therapy for refractory childhood uveitis","volume":"19","author":"Gallagher","year":"2007","journal-title":"Ophthalmol"},{"key":"R22-18-20210128","first-page":"1146","article-title":"Tumor necrosis factor-\u03b1 blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e3283060778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:57:15Z","timestamp":1620946635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200809000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3283060778","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}